Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis

(2020) Smruthi Vijayaraghavan et al.   MOLECULAR CANCER THERAPEUTICS

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

(2018) Amita Patnaik et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR- Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study

(2018) Giorgio V. Scagliotti et al.   Journal of Thoracic Oncology

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

(2018) Bushra Husain et al.   BIODRUGS

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

(2018) Geoffrey R. Oxnard et al.   JAMA Oncology

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

(2017) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer

(2016) Bok-Soon Lee et al.   ANNALS OF SURGICAL ONCOLOGY

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

(2016) Sheri L. Moores et al.   CANCER RESEARCH

A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors

(2016) Alexandra Gonzalez et al.   INTERNATIONAL JOURNAL OF CANCER

Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells

(2016) Katharine D. Grugan et al.   mAbs

Novel strategy for a bispecific antibody: induction of dual target internalization and degradation

(2016) J M Lee et al.   ONCOGENE

Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP)

(2015) Oscar Arrieta et al.   Journal of Thoracic Oncology

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab

(2015) Mareike Voigt et al.   NEOPLASIA

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

(2014) L. Liu et al.   CLINICAL CANCER RESEARCH

Controlled Fab-arm exchange for the generation of stable bispecific IgG1

(2014) Aran F Labrijn et al.   Nature Protocols

Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration-Effect Data to Support Clinical Development

(2013) H. Xiang et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1

(2012) Hartmut H. Niemann   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth

(2012) Paolo Luraghi et al.   Frontiers in Pharmacology

Role of MetMAb (OA-5D5) in c-MET active lung malignancies

(2011) Mosmi Surati et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort

(2011) Seiji Yano et al.   Journal of Thoracic Oncology

HGF-independent potentiation of EGFR action by c-Met

(2011) A M Dulak et al.   ONCOGENE

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

(2009) S Agarwal et al.   BRITISH JOURNAL OF CANCER

Targeting the c-MET signaling pathway for cancer therapy

(2008) Xiangdong Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

(2008) J. J. Lammerts van Bueren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA